JNCCN 360

Editor:

Jennifer R. Brown, MD, PhD

Advertisement

Advertisement

Recent News

Potential Prognostic Markers in CLL: NOTCH1 Pathway Mutations

Atrial Fibrillation After Treatment With Ibrutinib in Patients With CLL

Treatment of Resistant CLL With Acalabrutinib

Acalabrutinib Granted Breakthrough Therapy Designation in CLL

CLL14 Trial: Paired With Obinutuzumab, Venetoclax Versus Chlorambucil in CLL

Acalabrutinib in Relapsed or Refractory CLL

CLL12 Trial: Ibrutinib Improves Outcomes in Early-Stage CLL

RESONATE2 Update on First-Line Ibrutinib in Older Patients With CLL/SLL

Secondary Cancers and BTK Inhibitors for CLL

Umbralisib in Kinase Inhibitor–Intolerant CLL

Method for Selecting Potential Ibrutinib-Based Combinations in CLL

CD19-Directed Immunotherapy for Relapsed or Refractory CLL

FDA Approves Rituximab Biosimilar for CLL

Obesity and Chemoimmunotherapy Outcomes for Patients With CLL

FDA Approves Venetoclax Plus Obinutuzumab as First-Line Treatment for CLL/SLL

Concurrent CLL, Kaposi Sarcoma, and Angiosarcoma

Does Ibrutinib Pose Cardiac or Pulmonary Risk in Patients With CLL?

Does Size of Extracellular Vesicles Impact Immunotherapy for CLL?

EHA24 Congress: ASCEND Trial of Acalabrutinib Monotherapy in Resistant CLL

Sections

NCCN Resources

Copyright © 2019 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.